Since the introduction of FAB classification of acute leukemia in 1976, many studies
on its clinical significance have been reported.
Analyzed here 209 cases with acute leukemia observed at the Dept. of Internal
Medicine, Severance Hospital, YUMC, according to FAB classification ; and the results
observed were as follows :
1. ALL was 32.5% (L1 27.9%, L2 72.1%, L3
0.0%) and AML 67.5% (M1 45.4%, M2 15.6%,
M3 17.7%, M4 12.5%, M5 7.8%,
M6 1.4%).
2. Sex incidence(M : F ratio) was 2:1 in ALL and 1:1 in AML. Male predominance
was noted in L(3:1), but no significant difference in other subtypes.
3. Mean ago was 20.7 yrs. in ALL and 32.8 yrs. in AML without significant difference
between the subtypes. It was lowest in L1 (18.3 yrs).
4. Chief complaints were weakness(31.6%), fever(29.5%), dizziness(16.3%),
dyspnea(10.5%), headache(9.0%), and bleeding(6.8%) in orders without difference between
the subtypes.
5. High temperature was frequently noted in L1 (100.0%),
M2(94.7%) and M4(92.3%) with mean incidence of 88.5% in
ALL, 80.3% in AML, and 83.1% in total.
6. Bleeding tendency was predominant in M3(88.0%) and
M2(78.9%) with mean incidence of 50.9% in ALL, 66.1% in AML, and
61.6% in total.
7. Lymphadenopathy was frequent in L2(65.9%), M4(53.8%)
and M5(50.0%), with mean incidence of 59.1% in ALL, 36.1% in AML, and
43.6% in total.
8. Hepatomegaly was more frequent in L1(77.8%),
L2(71.1%), M4(69.2%) and M5(60.0%), with
mean incidence of 73.0% in ALL, 47.6% in AML, and 56.1% in total.
9. Splenomegaly was 58.1% in L2, 55.6% in L1 and 50.0%
in M4, with mean incidence of 57.4% in ALL, 23.8% in AML, and 35.0%
in total.
10. Anemia was somewhat more severe in M6 (mean Hb=5.9 gm%) and
M4(6.3gm%), without significant difference between the subtypes.
Leukocyte count is higher in ALL and M4 & M5 than other
subtypes, and lowest in M6. Thrombocytopenia is less prominent in
M4, M5, and L2.
11. Complete remission rate was 30.5% in ALL(L1 35.3%,
L2 27.9%), and 10.8% in AML; partial remission rate was 23.7% in
ALL(L1 41.2%, L2 16.3%) and 29.4% in
AML(M2 62.5%, M5 44.4%).
12. Median survival was 8.5 mos in ALL and 2.0 mos in AML from the onset of
symptoms; and 7.9 mos in ALL and 0.3 mos from the diagnosis. The more longer
survival was noted in L1 thats L2, and M2
than other myeloid subtypes.
|